Engineering Mesenchymal Stem Cells to Extend Healthspan: Therapeutic Potential, Challenges, and Future Solutions

Engineered mesenchymal stem cells (MSCs) have emerged as a promising therapeutic platform for extending healthspan. As agents of tissue repair and modulators of biological aging, MSCs have been widely studied for their capacity to enhance regeneration, restore immune homeostasis, and reduce chronic inflammation associated with age-related decline. This review examines emerging bioengineering strategies designed to overcome key age-related limitations in MSC homing, survival, and paracrine signaling, which have historically constrained their in vivo efficacy. We discuss major engineering approaches, including genetic modification, surface engineering, metabolic reprogramming, and preconditioning, with particular attention to their contributions to longevity-focused applications. Preclinical studies have demonstrated that engineered MSCs and their extracellular vesicles (EVs) yield measurable improvements in therapeutic performance. Reported benefits include prolonged persistence in inflamed tissues, partial reversal of senescence-associated phenotypes, and modulation of pro-aging inflammatory pathways. While MSC-derived EVs appear to offer a safer alternative with lower immunological risk, significant challenges persist in terms of manufacturing scalability, cargo consistency, and process standardization. The literature collectively supports that engineered MSC platforms have significant potential to contribute to healthspan extension. However, successful clinical translation will require a standardized manufacturing process to ensure therapeutic safety, reproducibility and efficacy in age-related conditions.